Canary Bio Appoints GMP Expert Youngsoo Son as Executive Director
Canaria Bio (CEO Han-Ik Na) has recruited Executive Director Young-Soo Son, who previously served as the Head of the Pharmaceutical Division at Isu Abxis. Executive Director Young-Soo Son is a talent who completed his doctoral coursework in Biochemical Engineering at Seoul National University College of Engineering. He has experience with about 10 projects involving antibody new drugs and biosimilars, having worked at Dong-A Pharmaceutical and Isu Abxis.
CEO Han-Ik Na stated, “Executive Director Young-Soo Son is a GMP expert who has experienced all production-related processes from cell line development to regulatory approval. We have formed an internal team to share tasks with Cytovance in the commercial production preparation process and process characterization. We expect the commercial production preparation period to be shortened,” explaining the reason for the recruitment.
Hot Picks Today
"Suspicious Timing?"...Trump Traded Stocks After Praising Wartime Capabilities
- "I Went to 10 Convenience Stores and Still Couldn't Buy It": The Bread Sensation That Sold 100 Million Units Already [The Way We Shop Now]
- [Breaking] Trump: "U.S. and Nigerian forces eliminate IS number two"
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "Contact Me First If Houses Are Built": Wealthy Clients Eyeing... Will Ultra-High-End Residences Worth 20 Billion Won Be Developed? [Real Estate AtoZ]
Executive Director Young-Soo Son will work together with Dr. Nageichi, a former US FDA production technology (CMC) inspector who recently joined Canaria Bio, on the commercial production preparation and the CMC section drafting of the Biologics License Application (BLA) for Oregobomab, an ovarian cancer treatment being developed by Canaria Bio.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
